Friday, February 12, 2016 3:02:27 PM
Remember this post from a few weeks ago?
Look familiar?
<No, not anytime now, actually it will be about 6 months from now when the real fun begins. It will look something like this after that.
1.68 Now ding ding ding! price is now 1.68!
2.57 Deliver Herpecide to Tox
4.49 Stellar Tox result
7.68 Phase I Stellar result
16.60 Phase II Stellar result
21.11 Flucide Tox stellar results plus Phase III Herpecide stellar results
47.70 100M plus profit on Ocular Herpecide. Sales projection on Genital, Lip and shingles 2.6 Billion, Manufacturing plant 2 underway to be completed in 9 months, Phase I and II Flucide complete, results Stellar.
347.44 Manufacturing complete for 20 plus kg per month Sales of all Herpecides over 1 billion 400M profit, Phase III Flucide complete, sales projection of 4.1 Billion.
My bad i missed a factor,
the numbers now come out like this.
2.47 now until tox delivery
4.11 delivered to tox
9.94 Phase I stellar result
19.14 Phase II
36.64 Flucide tox result plus phase III herpecide
61.14 phase I and II flucide plus Profits from ocular herpes announce new plant
368.55 phase III flucide sales projection and herpes 1 billion profit
Acquisition offer est 40B
Hows that buying at 1.05 and selling at 1.25 working out for you?
Remember these numbers!
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM